These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11064185)

  • 1. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
    Ator NA; Weerts EM; Kaminski BJ; Kautz MA; Griffiths RR
    Drug Alcohol Depend; 2000 Dec; 61(1):69-84. PubMed ID: 11064185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons.
    Ator NA
    Drug Alcohol Depend; 2000 Dec; 61(1):55-68. PubMed ID: 11064184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the behavioral effects of bretazenil and flumazenil in triazolam-dependent and non-dependent baboons.
    Weerts EM; Ator NA; Kaminski BJ; Griffiths RR
    Eur J Pharmacol; 2005 Sep; 519(1-2):103-13. PubMed ID: 16129429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.
    Weerts EM; Ator NA; Grech DM; Griffiths RR
    J Pharmacol Exp Ther; 1998 Apr; 285(1):41-53. PubMed ID: 9535993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of triazolam and zaleplon for sedation of dental patients.
    Flanagan D; Goodchild JH
    Dent Today; 2005 Sep; 24(9):64-6, 68-9. PubMed ID: 16229293
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.
    Troy SM; Lucki I; Unruh MA; Cevallos WH; Leister CA; Martin PT; Furlan PM; Mangano R
    J Clin Psychopharmacol; 2000 Jun; 20(3):328-37. PubMed ID: 10831020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents.
    Griebel G; Perrault G; Sanger DJ
    J Psychopharmacol; 1998; 12(4):356-65. PubMed ID: 10065909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of zaleplon, a non-benzodiazepine hypnotic, on melatonin secretion in rabbits.
    Noguchi H; Kitazumi K; Mori M; Shiobara Y; Shiba T
    J Pharmacol Sci; 2003 Oct; 93(2):204-9. PubMed ID: 14578589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of zaleplon on learning and memory in rats.
    Noguchi H; Kitazumi K; Mori M; Shiba T
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):183-8. PubMed ID: 12122506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
    Greenblatt DJ; Harmatz JS; von Moltke LL; Ehrenberg BL; Harrel L; Corbett K; Counihan M; Graf JA; Darwish M; Mertzanis P; Martin PT; Cevallos WH; Shader RI
    Clin Pharmacol Ther; 1998 Nov; 64(5):553-61. PubMed ID: 9834048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.
    Rush CR; Frey JM; Griffiths RR
    Psychopharmacology (Berl); 1999 Jul; 145(1):39-51. PubMed ID: 10445371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
    Sanger DJ; Morel E; Perrault G
    Eur J Pharmacol; 1996 Oct; 313(1-2):35-42. PubMed ID: 8905326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats.
    Noguchi H; Kitazumi K; Mori M; Shiba T
    J Pharmacol Sci; 2004 Mar; 94(3):246-51. PubMed ID: 15037809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral self-administration of triazolam, diazepam and ethanol in the baboon: drug reinforcement and benzodiazepine physical dependence.
    Ator NA; Griffiths RR
    Psychopharmacology (Berl); 1992; 108(3):301-12. PubMed ID: 1523281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zaleplon and driving impairment.
    Stillwell ME
    J Forensic Sci; 2003 May; 48(3):677-9. PubMed ID: 12762547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons.
    Weerts EM; Griffiths RR
    Behav Pharmacol; 1998 May; 9(3):285-97. PubMed ID: 9832941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
    Paronis CA; Cox ED; Cook JM; Bergman J
    Psychopharmacology (Berl); 2001 Aug; 156(4):461-8. PubMed ID: 11498724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects.
    Rush CR; Armstrong DL; Ali JA; Pazzaglia PJ
    J Clin Psychopharmacol; 1998 Apr; 18(2):154-65. PubMed ID: 9555600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem.
    Follesa P; Mancuso L; Biggio F; Cagetti E; Franco M; Trapani G; Biggio G
    Neuropharmacology; 2002 Feb; 42(2):191-8. PubMed ID: 11804615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.
    Greenblatt DJ; Harmatz JS; Walsh JK; Luthringer R; Staner L; Otmani S; Nedelec JF; Francart C; Parent SJ; Staner C
    Biopharm Drug Dispos; 2011 Dec; 32(9):489-97. PubMed ID: 21935965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.